Research Peptides for Sale in the EU 2026: Complete Buyer's Guide

In short: 5 tips for purchasing research peptides

For readers seeking research peptides for sale for laboratory work who wish to reach the recommendations directly, the following short summary condenses the rest of the article:

1. Purchase within the EU, not from overseas. Delivery within 1–3 business days, no customs complications, controlled cold-chain logistics and warranty claims under European law.
2. Require HPLC/MS testing and a per-batch COA. Purity ≥ 99 % (HPLC) and mass identity of the molecule (MS) constitute the absolute minimum for reproducible research.
3. Verify that the supplier clearly communicates RUO status (Research Use Only). A reputable EU supplier never promotes peptides for human use or dietary supplementation.
4. Monitor storage and transport. Lyophilisate at −20 °C, transport with a gel pack, delivery within 72 hours of dispatch.
5. Select by research category, not by trends. Regeneration, metabolism, longevity, cognition, performance and specialty peptides have distinct evidence bases and protocols.

Molequa® is a Slovak EU supplier covering all six categories under a unified HPLC/MS + per-batch COA standard. Details are provided in the individual sections below.

1. What research peptides are and what RUO status means

Research peptides are short amino acid chains, typically 3 to 50 residues, made by solid-phase peptide synthesis and sold strictly for laboratory work. RUO status means research use only: they are not medicines, supplements or cosmetics and are not intended for human or veterinary use. That status is not a formality, it defines what a supplier may legally claim.

RUO status entails that the molecule in question:

• is not a medicine registered with the EMA or ŠÚKL,
• is not a dietary supplement within the meaning of EU Regulation 1169/2011,
• is not a cosmetic or foodstuff,
• must not be sold for human or veterinary use.

Peptides such as BPC-157, TB-500, Retatrutide, Epithalon, GHK-Cu and others are available in the EU exclusively under this RUO regime. Clinical development (Phase 2/3, registration) for most of them has either been discontinued for financial reasons (Sikirić’s BPC-157 programme) or remains active for other molecules (e.g. Retatrutide at Eli Lilly).

A detailed introduction to peptide biochemistry is provided in the article What Are Peptides, Complete Guide.

2. Why purchase peptides within the EU rather than overseas

Buying inside the EU matters for three practical reasons: no customs clearance, delivery in days rather than weeks, and a supplier with a real legal entity you can hold to account. Most EU suppliers, including Molequa, source raw API abroad, but test and fill it in Europe. The difference is where accountability and quality control sit.

The research peptide market is global, the largest manufacturing base is in China (Shanghai, Hangzhou, Shenzhen). Most EU suppliers (including Molequa®) source raw API precisely from Chinese manufacturers, but with their own control pipeline and EU logistics. The difference between purchasing directly from overseas and from an EU supplier is substantial:

Customs and legislative aspects

For orders from China above €150, 21 % VAT applies, in addition to a customs declaration and a courier customs fee (typically €10–25). The real cost from overseas increases by 30–40 %. Shipments above €1,000 also require a customs declaration with an HS code, which for peptides lies in a grey zone.

Delivery time and cold chain

Overseas delivery typically requires 10–25 business days via DHL Express or standard post. The cold chain is interrupted during transport, Chinese manufacturers generally do not add a gel pack. An EU supplier delivers within 1–3 business days by courier (FedEx, Packeta) with a gel pack.

Quality control and complaints

In the event of an issue with purity or delivered quantity, a complaint from overseas is practically unenforceable. An EU supplier is subject to consumer protection law, GDPR and specific obligations toward customers (batch replacement, refund).

Batch control and COA

An established EU supplier re-tests the batch through an independent laboratory after import from overseas, independent HPLC/MS + LAL endotoxins. A Chinese manufacturer typically provides its own COA, which need not be verified by a third party.

Summary: The ostensibly “cheaper” prices from overseas, after accounting for VAT, customs, loss of quality and the risk of complaint, prove more expensive than an EU supplier, and without a guarantee of quality.

3. Six categories of research peptides in the EU catalogue

A serious catalogue is organised by research field, not by marketing claims. Molequa uses six categories: regenerative, metabolic, longevity, cosmetic, nootropic and specialised peptides. Grouping by target field rather than by promised effect is itself a signal, because catalogues sorted by outcome tend to be selling something a research supplier is not allowed to sell.

The Molequa® catalogue, like that of most reputable EU suppliers, categorises peptides by target research field rather than by marketing “effects”. The following six categories cover approximately 95 % of current EU research demand.

3.1 Regenerative peptides, BPC-157, TB-500

The category of regenerative peptides is historically the strongest. Two molecules dominate:

• BPC-157, a 15-amino acid peptide isolated from gastric juice (Sikirić, Zagreb, 1991). Angiogenesis via VEGFR2, fibroblast migration, GIT cytoprotection. Over 200 peer-reviewed publications.
• TB-500, a fragment of Thymosin β-4 (Goldstein, 1981). Actin regulation, stem cell mobilisation. Two Nature publications, Phase 2 trial REGENERATE-1.

The combination of BPC-157 + TB-500 is referred to in the research literature as the “gold-standard regenerative research pair”. A detailed comparison of mechanisms is available in BPC-157 vs TB-500.

3.2 Metabolic peptides, Retatrutide, Cagrilintide, Mazdutide, AOD-9604, 5-Amino-1MQ

The category of metabolic peptides is the fastest growing following the emergence of incretin agonists (GLP-1, GIP, glucagon). The dominant molecules include:

• Retatrutide, a triple agonist of GLP-1/GIP/glucagon (Eli Lilly), Phase 3 active. The strongest result for modelling weight reduction in the preclinical literature 2023 to 2025.
• Cagrilintide, an amylin analogue combined with semaglutide in the CagriSema programme (Novo Nordisk).
• Mazdutide, a dual GLP-1/glucagon agonist (Innovent), Phase 3 completed in China.
• AOD-9604, the 176-191 fragment of growth hormone, historically used for modelling lipolysis.
• 5-Amino-1MQ, a small molecule (not a peptide in the strict sense), an inhibitor of the NNMT enzyme.

The metabolic category requires above all precise concentration and solution stability, errors in reconstitution can shift research outcomes by tens of percent.

3.3 Longevity peptides, Epithalon, MOTS-c, NAD+

The category of longevity peptides is the most contested in terms of evidence base, telomere biology, mitochondrial signalling and NAD+ metabolism are active fields, but clinical data in humans are limited.

• Epithalon (Epitalon), a 4-amino acid peptide (Ala-Glu-Asp-Gly) of pineal origin (Khavinson). Investigated for telomere-maintenance effects in Russian literature.
• MOTS-c, a 16-amino acid mitochondrial peptide (encoded by mtDNA), investigated for insulin sensitivity and exercise-mimetic effects. The mechanism and the published studies are covered in the MOTS-c research guide.
• NAD+, nicotinamide adenine dinucleotide, a coenzyme (not a peptide in the strict sense), investigated for sirtuin signalling.

3.4 Cognitive peptides, Semax, Selank, DSIP

The category of cognitive peptides is dominated by the Russian developmental school. These molecules were originally developed in the Soviet Union / Russian Federation as clinical therapeutics (many are registered as medicines in Russia); in the EU, however, they exist exclusively under the RUO regime.

• Semax, a heptapeptide derived from ACTH(4-10), investigated for BDNF signalling and neuroprotection after ischaemia.
• Selank, a heptapeptide derived from tuftsin, investigated for non-sedating anxiolysis.
• DSIP (Delta Sleep-Inducing Peptide), a 9-amino acid peptide, investigated for delta-sleep signalling.

Cognitive peptides are typically supplied via intranasal spray, requiring a specific reconstitution medium (saline + benzalkonium).

3.5 Performance peptides, HGH Fragment 176-191

The category of performance peptides contains molecules historically studied in sports science. Most of these peptides are on the WADA Prohibited List, a relevant consideration when publishing sports-science results.

• HGH Fragment 176-191, the C-terminal fragment of growth hormone, investigated for selective lipolytic signalling without engagement of the GH axis. Of interest for metabolic research without concomitant effects on IGF-1.

Related molecules include GHRH analogues (CJC-1295, Tesamorelin) and GHRP peptides (Ipamorelin, Hexarelin), in the Molequa catalogue where relevant, or in other categories. The blend of both pathways is listed as Ipamorelin + CJC-1295, lyophilised, HPLC purity of at least 99 % and a batch-specific certificate of analysis.

3.6 Specialty peptides, GHK-Cu, Argireline, PT-141, Melanotan 2

The category of specialty peptides encompasses molecules with narrow targets, skin, the melanocortin axis, sexual signalling.

• GHK-Cu, the Gly-His-Lys tripeptide complexed with copper. One of the best-documented molecules in dermatological research, activating regenerative genes (Pickart, 250+ publications).
• Argireline, a hexapeptide (acetyl hexapeptide-3), originally dermato-cosmetic. SNARE inhibition.
• PT-141 (Bremelanotide), a melanocortin agonist, clinically registered in the U.S. for HSDD (Vyleesi).
• Melanotan 2, a non-selective melanocortin agonist, investigated for pigmentation.

4. How to recognise a quality supplier, 7 criteria

Seven things separate a real supplier from a reseller: independent third-party testing, a certificate of analysis tied to the exact batch, HPLC and MS methods, a registered EU legal entity, a real address and phone number, clear RUO labelling, and shipping from an EU warehouse. Independent testing is the one that cannot be faked, because the laboratory can be contacted directly.

This is the most important section of the article. The distinction between a reputable EU supplier and a “garage” reseller is not always evident from the website, specific criteria must be examined.

4.1 HPLC/MS testing per batch

HPLC (High-Performance Liquid Chromatography) measures peptide purity, the percentage of the sample constituted by the target molecule versus by-products of synthesis (deletions, adducts, oxidised forms). The standard for research peptides is ≥ 99 % HPLC purity.

MS (Mass Spectrometry) confirms molecular identity, measuring the molecular mass and matching it against the theoretical value. Without MS confirmation, it is uncertain whether the synthesis delivered the correct sequence.

A quality supplier publishes the HPLC chromatogram + MS spectrum directly in the COA for the specific batch.

4.2 COA (Certificate of Analysis) per batch

COA is the official document summarising analytical results for a given batch. It must contain:

• the peptide name, sequence and molecular mass,
• batch number, synthesis date and expiration date,
• HPLC purity (%),
• MS confirmation of identity (observed vs theoretical mass),
• water content (Karl Fischer titration),
• acetate / TFA counter-ion content,
• endotoxin testing (LAL test),
• signature of the QA officer.

“COA on request” without stating a batch is a red flag, a reputable supplier provides COAs for direct download on the product page.

4.3 Independent laboratory

Ideally, HPLC/MS is analysed not by the manufacturer itself but by an independent accredited laboratory. In practice this implies ISO 17025 accreditation or a third-party audit. In the EU, such laboratories are provided by Eurofins, SGS or local academic laboratories, among others.

4.4 EU regulatory compliance + clear RUO framing

The supplier’s website must unambiguously communicate RUO status in the terms and conditions, on product pages and in the footer. Claims such as “great for weight loss”, “treats joints”, “anti-ageing” in a commercial context indicate that the supplier is violating EU Regulation 1924/2006 on health claims and is exposed to sanctions by ŠÚKL/SOI.

A reputable EU supplier also clearly describes the mechanism and references PubMed literature without human claims.

4.5 Storage at −20 °C

Lyophilised peptides are stable at −20 °C typically for 24–36 months, at +4 °C for 6–12 months, and at room temperature for only weeks. A reputable supplier stores batches in freezer boxes at −20 °C and dispatches directly from this temperature.

4.6 Transport with gel pack + rapid delivery

Transport of lyophilisate requires a gel pack (cooling gel) in a thermal package so that the temperature remains below +8 °C during 24–72 hours. Delivery within 1–3 business days by courier (FedEx, Packeta) within the EU is standard. Dispatch directly from the warehouse, not dropshipping from China.

4.7 Transparent purity ≥ 99 %

Declared HPLC purity must be ≥ 99 % for serious research work. Purity of 95–98 % is acceptable for preliminary screening; < 95 % is problematic for replicable publication data. Molequa® declares HPLC ≥ 99 % for all catalogue products.

5. Prices of research peptides in 2026, indicative overview

Prices vary by peptide and vial size, and per milligram the larger vial is almost always cheaper. Retatrutide and cagrilintide sit at the top of the range, GHK-Cu and NAD+ at the bottom. Current figures are in the catalogue rather than here, because they shift with batch and supplier and a stale number in an article helps nobody.

The following table summarises indicative prices (EUR) in the Molequa® EU catalogue for the most frequently ordered research peptides. Prices are comparable to those of other established EU suppliers (typically ±15 %).

Note: Prices are indicative for 2026; the current price list is available directly in the Molequa e-shop. Prices per mg typically decrease by 10–35 % with larger packaging.

6. How to store research peptides properly

Store the lyophilizate at minus 20 degrees and the reconstituted solution at 2 to 8 degrees, upright and away from light. Never freeze a peptide once it is in solution, because ice crystals damage the molecule. After reconstitution with a preserved solvent, most peptides remain usable for two to four weeks.

A high-quality synthesised peptide loses value if improperly stored or reconstituted. The basic rules are as follows:

• Lyophilisate should be stored at −20 °C until reconstitution. Shelf life 24–36 months.
• After reconstitution, storage should be at +2 to +8 °C. Shelf life typically 14–28 days, depending on the peptide.
• For multiple withdrawals, laboratory practice uses bacteriostatic water (BAC water, 0.9 % benzyl alcohol); for single use, sterile water.
• Do not refreeze after reconstitution, crystallisation damages peptide bonds.

7. Molequa® catalogue versus the competition

Roughly 15 to 20 established research peptide suppliers operate in the EU, mostly in Germany, Austria, the Netherlands and the Czech Republic. What differentiates them is rarely the molecule, which often comes from the same manufacturing base, but the documentation behind it. Molequa publishes independent Janoshik testing and will supply the raw chromatogram on request.

Approximately 15–20 established suppliers of research peptides currently operate in the EU, mostly in Germany, Austria, the Netherlands and the Czech Republic. The Slovak market is dominated by Molequa®, which is the sole Slovak supplier with its own complete catalogue covering all six categories.

Molequa® differentiators:

• Slovak supplier, full invoicing and support in Slovak, delivery within 1–2 business days to SK/CZ.
• HPLC/MS + COA per batch, for all catalogue products, COA available for download on the product page.
• Purity ≥ 99 % declared across the entire catalogue.
• Own cold-chain warehouse at −20 °C, dispatch with gel pack.
• Scientific content, for each peptide, a detailed guide with PubMed citations (not marketing claims).
• Legal framework, clear RUO framing, terms and conditions consistent with EU legislation.

Most foreign competitors lack Slovak localisation, which for Slovak researchers presents difficulties with complaints, communication with the supplier and accounting (purchase in EUR from within the EU versus outside).

8. Frequently asked questions about purchasing peptides in the EU

What is the difference between a research peptide and an approved medicine?

A research peptide is a molecule intended for laboratory scientific research without clinical registration (RUO). An approved medicine has undergone Phase 1/2/3 clinical trials and is registered with the EMA or a national medicines agency for a specific indication. Most research peptides (BPC-157, TB-500, Epithalon) have not achieved clinical registration; some hold it in other jurisdictions (PT-141 in the U.S.); others are actively progressing through Phase 3 (Retatrutide).

Why purchase peptides within the EU and not from China?

Delivery within 1–3 days rather than 10–25 days, no customs fees or 21 % VAT added on import, cold-chain logistics with gel pack, the option of complaints under EU consumer protection law and independent HPLC/MS verification of the batch. The real cost from overseas, accounting for all factors, is typically higher than from an EU supplier such as Molequa®.

What is a COA and why is it important?

A COA (Certificate of Analysis) is the official analytical document for a specific peptide batch. It contains HPLC purity, MS identity confirmation, water content, endotoxins and the batch number. Without a COA there is no verification of quality, and without a batch-specific COA (rather than a generic one) there is no auditable record for publication.

What is the normal purity of a quality research peptide?

The standard for publishable research is HPLC purity ≥ 99 %. Purity of 95–98 % is acceptable for preliminary screening but not for quantitative data. Molequa® declares ≥ 99 % for the entire catalogue.

How long does delivery of peptides take within the EU?

From Molequa® typically 1–2 business days to Slovakia and the Czech Republic, and 2–3 business days to the rest of the EU. By FedEx or Packeta courier, with a gel pack in a thermal package. Orders placed by 14:00 are dispatched on the same day.

How should lyophilised peptide be stored properly?

Lyophilisate at −20 °C, shelf life 24–36 months, protected from light and moisture. After reconstitution, +2 to +8 °C typically for 14–28 days. The reconstituted solution should not be refrozen. Details are provided in the article Lyophilisate Reconstitution.

Are research peptides legal in the Slovak Republic?

Yes, provided they are sold under the RUO regime for laboratory scientific research. Sale for human use, declaration as a medicine or dietary supplement is contrary to legislation (Act No. 362/2011 on medicines, EU Regulation 1924/2006 on health claims). Molequa® and other reputable EU suppliers sell exclusively under the RUO regime.

9. Key scientific figures and citations

The research peptide market is an established scientific discipline with decades of peer-reviewed literature. The following key figures illustrate its scope:

“Peptides represent an emerging class of therapeutic molecules with over 80 approved drugs on the global market and more than 400 in clinical development. Their advantages over small molecules include higher target specificity and lower toxicity, though challenges in oral bioavailability and metabolic stability remain active research areas.” Wang L. et al. (2022), Signal Transduction and Targeted Therapy 7:48, PubMed 35165272

Key figures for peptide research 2026

• 80+ clinically approved peptide medicines on the global market (2024).
• 400+ peptides in clinical development (Phase 1–3, 2024).
• > 7,000 peptide publications indexed in PubMed annually (2020–2024).
• > 200 publications for BPC-157 alone (Sikirić group + replications).
• > 250 publications for GHK-Cu (Pickart + international laboratories).
• 2 Nature publications for Thymosin β-4 (Bock-Marquette 2004, Smart 2007).
• Phase 3 programme active for Retatrutide (Eli Lilly, 2024–2026).
• ~99 % HPLC purity, the standard for a publishable research peptide.

Reference sources (PubMed)

1. Henninot A., Collins J.C., Nuss J.M. (2018). “The Current State of Peptide Drug Discovery: Back to the Future?” J Med Chem 61(4):1382–1414. PubMed 28737935
2. Lau J.L., Dunn M.K. (2018). “Therapeutic peptides: Historical perspectives, current development trends, and future directions.” Bioorg Med Chem 26(10):2700–2707. PubMed 28720325
3. Wang L., Wang N., Zhang W., et al. (2022). “Therapeutic peptides: current applications and future directions.” Signal Transduct Target Ther 7:48. PubMed 35165272

Scope of this article: This article summarises the scientific literature on research peptides in the EU market context and does not present therapeutic claims. The product is sold strictly for laboratory scientific research (RUO).

Further reading

Categories of research peptides:

• Regenerative peptides, BPC-157, TB-500
• Metabolic peptides, Retatrutide, Cagrilintide, Mazdutide, AOD-9604
• Longevity peptides, Epithalon, MOTS-c, NAD+
• Cognitive peptides, Semax, Selank, DSIP
• Performance peptides, HGH Fragment 176-191
• Specialty peptides, GHK-Cu, Argireline, PT-141, Melanotan 2

Top product pages:

• BPC-157, complete guide
• TB-500, complete guide
• GHK-Cu, complete guide
• Retatrutide, complete guide

Practical guides:

• What Are Peptides, complete guide
• BPC-157 vs TB-500, in-depth comparison

Legal notice

All Molequa® products, including BPC-157, TB-500, Retatrutide, GHK-Cu and all other molecules in the catalogue, are intended exclusively for research and scientific purposes (Research Use Only). They are not a medicine, dietary supplement, cosmetic product or foodstuff. They are not intended for human or animal consumption. Sale is restricted to qualified researchers, academic institutions and laboratories. Before any handling, the relevant scientific literature should be consulted and applicable legislation in the user’s jurisdiction should be observed.

Author: Molequa® Research Team Publication date: 2 July 2026 Last update: 2 September 2026 Reading time: ~12 min